Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HASSAN AWAD ABOUHOULI

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1366564304
CMS profile
16211
Location
TULSA, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$12,454.27

131 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HASSAN AWAD ABOUHOULI

NPI 1366564304 · CMS profile ID 16211

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

TULSA, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366564304?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HASSAN AWAD ABOUHOULI, NPI 1366564304, CMS profile ID 16211. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366564304?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HASSAN AWAD ABOUHOULI, NPI 1366564304, CMS profile ID 16211. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366564304?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HASSAN AWAD ABOUHOULI, NPI 1366564304, CMS profile ID 16211, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1366564304?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

131 matching records · $12,454.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 131 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–131 of 131.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $55.1803/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104447813 CMS
AstraZeneca Pharmaceuticals LP $147.4003/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105631591 CMS
AstraZeneca Pharmaceuticals LP $250.0003/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105650034 CMS
GlaxoSmithKline, LLC. $9.5402/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116315596 CMS
GENZYME CORPORATION $27.2202/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139911987 CMS
AstraZeneca Pharmaceuticals LP $28.0202/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105430769 CMS
Regeneron Healthcare Solutions, Inc. $14.1502/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113993405 CMS
United Therapeutics Corporation $23.8102/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149451345 CMS
GENZYME CORPORATION $42.7602/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139912045 CMS
AstraZeneca Pharmaceuticals LP $16.0502/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104278237 CMS
GlaxoSmithKline, LLC. $12.6202/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115974589 CMS
Mylan Specialty L.P. $23.4902/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147308417 CMS
Pulmonx Corporation $25.1602/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087845394 CMS
Actelion Pharmaceuticals US, Inc. $23.1202/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078908057 CMS
Amgen Inc. $24.5502/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111508333 CMS
INOGEN, INC. $11.4901/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144987030 CMS
Mylan Specialty L.P. $22.2701/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147311277 CMS
GENZYME CORPORATION $27.9301/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139911975 CMS
GlaxoSmithKline, LLC. $14.7201/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116316292 CMS
Mallinckrodt Hospital Products Inc. $28.6401/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145044199 CMS
AstraZeneca Pharmaceuticals LP $171.1101/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105424974 CMS
AstraZeneca Pharmaceuticals LP $19.0701/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105755355 CMS
GENZYME CORPORATION $28.9201/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139911977 CMS
GlaxoSmithKline, LLC. $4.5501/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116125436 CMS
GlaxoSmithKline, LLC. $0.9201/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116364649 CMS
GlaxoSmithKline, LLC. $11.2301/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116601209 CMS
GlaxoSmithKline, LLC. $5.6601/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116634938 CMS
AstraZeneca Pharmaceuticals LP $18.4601/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104547476 CMS
GENZYME CORPORATION $27.4501/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139911973 CMS
GlaxoSmithKline, LLC. $6.4701/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116317620 CMS
Pulmonx Corporation $26.2501/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087845392 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11,913.01 100
PY2020 $13,288.64 110
PY2021 $20,058.12 142
PY2022 $14,325.85 113
PY2023 $18,201.10 159
PY2024 $12,454.27 131
PY2025 $13,031.61 138

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $877,701.96 55
PY2024 Principal investigator $888,540.64 132
PY2023 Principal investigator $258,679.75 64
PY2022 Principal investigator $24,029.37 5
PY2021 Principal investigator $12,623.79 4
PY2020 Principal investigator $49,176.01 1
PY2019 Principal investigator $32,851.62 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $1,250.00 12/12/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620848
Principal investigator 1 PFIZER INC. $13,762.00 12/11/2025 Non-covered Recipient Entity
Layrek Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228725844
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,477.90 12/11/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049303
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,995.90 12/11/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049305
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,718.70 12/11/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049307
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,345.30 12/04/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049301
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,693.10 11/26/2025 Non-covered Recipient Entity
LAYREK CLINICAL RESEARCH
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) No dispute reported 06/30/2026 1185554849
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,375.55 11/13/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049299
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,810.80 10/23/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049297
Principal investigator 1 PFIZER INC. $1,339.39 10/19/2025 Non-covered Recipient Entity
LAYREK CLINICAL RESEARCH
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228729399
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,394.60 10/14/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049295
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $179.90 09/30/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244049309
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,985.80 09/17/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049293
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $400.00 09/11/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049291
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,319.60 08/19/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049289
Principal investigator 1 Genentech, Inc. $920.00 08/06/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620834
Principal investigator 1 Genentech, Inc. $54.00 08/06/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620843
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $393.00 07/25/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049285
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $162.50 07/25/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049287
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,319.60 07/24/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049283
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,345.30 07/18/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049281
Principal investigator 1 Genentech, Inc. $4,410.00 07/09/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620830
Principal investigator 1 Genentech, Inc. $1,517.00 07/02/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620839
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,523.60 06/24/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049279
Principal investigator 1 Genentech, Inc. $6,804.00 06/18/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620799
Principal investigator 1 Genentech, Inc. $1,430.00 06/11/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620823
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,068.80 06/05/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049277
Principal investigator 1 Genentech, Inc. $5,520.00 06/04/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620827
Principal investigator 1 Genentech, Inc. $2,790.00 05/28/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620804
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 05/07/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049313
Principal investigator 1 Genentech, Inc. $920.00 04/30/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620808
Principal investigator 1 Genentech, Inc. $6,440.00 04/25/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620795
Principal investigator 1 Genentech, Inc. $2,036.85 04/25/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620819
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,309.90 04/24/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049275
Principal investigator 1 AstraZeneca Pharmaceuticals LP $220,260.45 04/23/2025 Non-covered Recipient Entity
LAYREK CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185554839
Principal investigator 1 Genentech, Inc. $920.00 04/11/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620815
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,051.90 04/10/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049273
Principal investigator 1 Genentech, Inc. $920.00 04/04/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620811
Principal investigator 1 Genentech, Inc. $4,600.00 03/28/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620783
Principal investigator 1 AstraZeneca Pharmaceuticals LP $53,415.00 03/26/2025 Non-covered Recipient Entity
LAYREK CLINICAL RESEARCH
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185554847
Principal investigator 1 Genentech, Inc. $3,680.00 03/21/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620790
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,034.80 03/20/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049271
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $862.40 03/13/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049267
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $685.50 03/13/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049269
Principal investigator 1 Genentech, Inc. $1,840.00 03/05/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620775
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,340.20 02/27/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049265
Principal investigator 1 Genentech, Inc. $1,500.00 02/26/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620786
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/21/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049311
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $68,248.00 02/12/2025 Non-covered Recipient Entity
Layrek Clinical Research
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1235996233
Principal investigator 1 Genentech, Inc. $5,520.00 02/12/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620779
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,303.81 01/31/2025 Non-covered Recipient Entity
LAYREK CLINICAL RESEARCH
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185554841
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,803.80 01/30/2025 Non-covered Recipient Entity
LAYREK MANAGEMENT LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244049263
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $53,440.21 01/21/2025 Non-covered Recipient Entity
Layrek Clinical Research
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis No dispute reported 06/30/2026 1235996231
Principal investigator 1 AstraZeneca Pharmaceuticals LP $113,994.49 01/17/2025 Non-covered Recipient Entity
LAYREK CLINICAL RESEARCH
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 No dispute reported 06/30/2026 1185554845
Principal investigator 1 AstraZeneca Pharmaceuticals LP $150,995.51 01/03/2025 Non-covered Recipient Entity
LAYREK CLINICAL RESEARCH
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185554843